Abstract
Patients with asthma exhibit heterogeneous responses to all classes of asthma medication. This review examines clinical characteristics, biomarkers of inflammation, and genetic polymorphisms associated with treatment responsiveness in studies of adults and children with asthma, with an emphasis on inhaled corticosteroids and leukotriene modifiers. Recent clinical studies extended previous observations of associations between biomarkers of allergic inflammation and responsiveness to inhaled corticosteroids, and between cigarette smoke exposure and responsiveness to montelukast. Pharmacogenetic studies revealed associations between treatment response and genetic variations in CRHR1, as well as a number of genes encoding proteins involved in the absorption, production, and action of the cysteinyl leukotrienes. Very few studies have attempted to test the ability of these phenotypic and genotypic associations to predict treatment responsiveness. Additional prospective studies of sufficient size, quality, and ethnic diversity are needed to determine how best to incorporate information about genetic variations, clinical characteristics, and biomarkers into decisions about asthma therapy for individual patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
